Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Convertible Debt: 2023-2024

Historic Convertible Debt for China SXT Pharmaceuticals (SXTC) over the last 2 years, with Mar 2024 value amounting to $2.8 million.

  • China SXT Pharmaceuticals' Convertible Debt rose 94.04% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 94.04%. This contributed to the annual value of $2.8 million for FY2024, which is 10.15% down from last year.
  • As of FY2024, China SXT Pharmaceuticals' Convertible Debt stood at $2.8 million, which was down 10.15% from $3.1 million recorded in FY2023.
  • In the past 5 years, China SXT Pharmaceuticals' Convertible Debt ranged from a high of $3.1 million in FY2023 and a low of $2.8 million during FY2024.
  • In the last 2 years, China SXT Pharmaceuticals' Convertible Debt had a median value of $3.0 million in 2023 and averaged $3.0 million.
  • Data for China SXT Pharmaceuticals' Convertible Debt shows a maximum YoY decreased of 10.15% (in 2024) over the last 5 years.
  • Over the past 2 years, China SXT Pharmaceuticals' Convertible Debt (Yearly) stood at $3.1 million in 2023, then fell by 10.15% to $2.8 million in 2024.